When viewing this topic in a different language, you may notice some differences in the way the content is structured, but it still reflects the latest evidence-based guidance.

Common cutaneous drug reactions

Evidence last reviewed: 22 Apr 2026
Topic last updated: 22 Nov 2024

Summary

განსაზღვრება

ანამნეზი და გასინჯვა

ძირითადი დიაგნოსტიკური ფაქტორები

  • history of drug exposure
  • skin lesions
  • variable skin reactions within 5 to 15 minutes of drug exposure
  • variable skin reactions within a few hours of drug exposure
  • variable skin reactions within 2 weeks of drug exposure
  • variable skin reactions within months to years of drug exposure
  • previous exposure and reaction to drug
სრული ტექსტი

სხვა დიაგნოსტიკური ფაქტორები

  • pruritus
  • associated noncutaneous features
  • pain
სრული ტექსტი

რისკფაქტორები

  • virus infections
  • HIV infection
  • HLA-B*5701 polymorphism
  • HLA-B*1502 polymorphism
  • HLA-B*5801 polymorphism
  • female sex
სრული ტექსტი

დიაგნოსტიკური კვლევები

Tests to avoid

  • immunoglobulin G (IgG) allergy testing
სრული ტექსტი

გასათვალისწინებელი კვლევები

  • blood (whole blood, plasma, serum) drug concentration
  • serum tryptase concentration (anaphylaxis)
  • complement pathway assay
  • histology of lesion biopsy
  • CBC and differential
  • antihistone antibodies to single-stranded DNA (lupus-like syndrome)
  • skin tests (prick tests, intradermal tests, patch tests)
  • drug-specific IgE
სრული ტექსტი

ახალი ტესტები

  • basophil activation test
  • lymphocyte proliferation assay (LPA/LTT)
  • enzyme-linked immunospot assay (ELISPOT test)

მკურნალობის ალგორითმი

მწვავე

serious cutaneous adverse reactions

nonserious cutaneous adverse reactions

მიმდინარე

following acute episode

კონტრიბუტორები

ავტორები

Michael Ardern-Jones, BSc, MBBS, DPhil, FRCP

Associate Professor

Consultant Dermatologist

Faculty of Medicine

University of Southampton

Southampton

UK

Disclosures

MA-J declares that he has no competing interests.

Acknowledgements

Dr Michael Ardern-Jones would like to gratefully acknowledge Dr Wei Yann Haw, Dr Anne Holbrook, Dr Hermenio Lima, and Dr Jeffrey K. Aronson, the previous contributors to this topic.

Disclosures

WYH, AH and HL declare that they have no competing interests. JKA is editor of Meyler's Side Effects of Drugs and its annual companion volumes, the Side Effects of Drugs Annuals.

Peer reviewers

Shahbaz A. Janjua, MD

Specialist Dermatologist

Ayza Skin & Research Center

Lalamusa

Pakistan

Disclosures

SAJ declares that he has no competing interests.

Craig K. Svensson, Pharm.D, PhD

Dean

College of Pharmacy, Nursing, and Health Sciences

Purdue University

West Lafayette

IN

Disclosures

CKS declares that he has no competing interests.

Peer reviewer acknowledgements

BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.

Disclosures

Peer reviewer affiliations and disclosures pertain to the time of the review.

References

Our in-house evidence and editorial teams collaborate with international expert contributors and peer reviewers to ensure that we provide access to the most clinically relevant information possible.

Key articles

Aronson JK, Ferner RE. Joining the DoTS: new approach to classifying adverse drug reactions. BMJ. 2003 Nov 22;327(7425):1222-5. Abstract

Gell PG, Coombs RRA, eds. Clinical aspects of immunology. 1st ed. Oxford: Blackwell; 1963.

Bigby M, Jick S, Jick H, et al. Drug-induced cutaneous reactions: a report from the Boston Collaborative Drug Surveillance Program on 15,438 consecutive inpatients, 1975 to 1982. JAMA. 1986 Dec 26;256(2):3358-63. Abstract

Kuokkanen K. Drug eruptions: a series of 464 cases in the Department of Dermatology, University of Turku, Finland, during 1966-1970. Acta Allergol. 1972 Dec;27(5):407-38. Abstract

Aronson JK, Ferner RE. Clarification of terminology in drug safety. Drug Saf. 2005;28(10):851-70. Abstract

Khan DA, Banerji A, Blumenthal KG, et al. Drug allergy: a 2022 practice parameter update. J Allergy Clin Immunol. 2022 Dec;150(6):1333-93.Full text  Abstract

Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981 Aug;30(2):239-45. Abstract

Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965 Jan;58(1):295-300.Full text  Abstract

Howick J, Glasziou P, Aronson JK. The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute? J R Soc Med. 2009 May;102(5):186-94.Full text  Abstract

National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. September 2014 [internet publication].Full text

Reference articles

A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
  • Common cutaneous drug reactions images
  • Differentials

    • Systemic lupus erythematosus
    • Autoimmune blistering disorders
    • Staphylococcal scalded skin syndrome
    More Differentials
  • Guidelines

    • Anaphylaxis: a 2023 practice parameter update
    • Drug allergy: a 2022 practice parameter
    More Guidelines
  • padlock-lockedLog in or subscribe to access all of BMJ Best Practice

Use of this content is subject to our disclaimer